Hepatic Insufficiency Clinical Trial
Official title:
A 2-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of ACP-196
The study will evaluate the influence of hepatic insufficiency on the PK of ACP-196.
This is a 2-part study. Part 1 of the study will compare the PK of ACP-196 in participants with mild hepatic insufficiency (a score of 5 to 6, on the Child-Pugh scale) and moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) to healthy (mean) matched control participants for age and weight. Part 2 of the study, if it is conducted, will compare the PK of ACP-196 in participants with severe hepatic insufficiency (a score of 10 to 15 on the Child-Pugh scale) to the healthy control participants from Part 1. In Part 1, 6 participants with mild hepatic insufficiency, 6 participants with moderate hepatic, and 6 healthy control participants matched to the hepatic insufficiency groups according to mean age and mean weight will be enrolled. In Part 2, if conducted, 6 participants with severe hepatic insufficiency will be enrolled. The control group of Part 1 will be used for Part 2 PK comparison. Participants will be screened within 28 days before the dose. Participants will be contacted approximately 14 days after the last dose of study drug administration to determine if any adverse event has occurred since the last dose of study drug. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04097704 -
Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort
|
||
| Completed |
NCT02161224 -
A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function
|
Phase 1 | |
| Completed |
NCT00929032 -
Liver Transplantation and Reticuloendothelial Clearance Capacity
|
N/A | |
| Completed |
NCT00509210 -
Study of Telaprevir in Subjects With Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT02894385 -
Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)
|
Phase 1 | |
| Completed |
NCT03306667 -
Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)
|
Phase 1 | |
| Not yet recruiting |
NCT05093972 -
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
|
Phase 1 | |
| Terminated |
NCT02457702 -
Mitochondrial Function in Patients With Severe Liver Disease
|
N/A | |
| Completed |
NCT02090621 -
Extracorporeal Photopheresis After Liver Transplant
|
Phase 2 | |
| Completed |
NCT02249442 -
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
|
Phase 1 | |
| Completed |
NCT03341884 -
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants
|
Phase 1 | |
| Completed |
NCT01475136 -
A Study of LY2140023 in Hepatically-Impaired Participants
|
Phase 1 | |
| Completed |
NCT00968591 -
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
|
Phase 1 | |
| Completed |
NCT00969813 -
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
|
Phase 1 | |
| Completed |
NCT00931060 -
Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects
|
N/A | |
| Completed |
NCT00416702 -
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
|
Phase 1 | |
| Completed |
NCT03968848 -
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
|
Phase 1 | |
| Recruiting |
NCT05209295 -
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
|
Phase 1 | |
| Completed |
NCT00692341 -
Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT00314054 -
Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults
|
Phase 1 |